Precigen Inc
NASDAQ:PGEN
Precigen Inc
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 456 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The firm also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. The company also has a robust pipeline of preclinical programs.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 456 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The firm also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. The company also has a robust pipeline of preclinical programs.
First FDA Approval: PAPZIMEOS was fully approved in August as the first and only available treatment for adult RRP, with a broad label for all adult patients.
Strong Clinical Results: PAPZIMEOS showed a 51% complete response rate, 86% reduction in surgical burden, and a strong safety profile.
Rapid Commercial Rollout: The full sales team was deployed in September, drug shipments have begun, and over 100 patients are registered for treatment.
Payer Progress: Over 80 million insured lives are already covered, including Medicare and Medicaid, and further coverage updates are expected soon.
Financial Position: Company ended Q3 with $123.6 million in cash and expects this plus PAPZIMEOS revenues to fund operations to cash breakeven by end of 2026.
Manufacturing Ready: In-house cGMP manufacturing is fully operational and meeting both current and expected demand.
Guidance: Gross-to-net revenue adjustment is expected in the high teens to low 20% range, consistent with peers.
